01Dec
Americas Antitrust Review 2021
Covid-19 has made 2020 into a year like no other with ‘stay at home’ orders and working from home the new normal. Nonetheless, the tech and pharma industries continued to attract immense antitrust scrutiny, with daily reports in the media and pressure from politicians to address what some perceive to be anticompetitive mergers by digital platforms and pharmaceutical companies, even while innovation in both sectors continues at breakneck speed. In this article, we discuss some of the most...
By:
Cooley LLP
Related
On February 20, 2020, at its monthly public meeting, the California Occupational Safety and Health S...
Read More >
In In Re: Appraisal of Jarden Corporation, C.A. No. 12456-VCS (Del. Ch. Jul. 19, 2019), the Delaware...
Read More >
The current COVID-19 pandemic is causing an unprecedented negative impact on businesses around the g...
Read More >
Requirement to Report - For (1) any exercise of an incentive stock option (ISO) during 2019 or (2) ...
Read More >
The Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) requires parties to transactions meet...
Read More >
This quarter’s issue includes summaries and associated court opinions of selected cases principally...
Read More >